Facts

Corporate

Mission: We create novel protein drugs with the potential to significantly help patients fight their diseases.

History: ZymoGenetics, Inc. was founded in 1981 by three noted university professors: Earl W. Davie, Professor of Biochemistry at the University of Washington; Benjamin D. Hall, Professor of Genetics at the University of Washington; and Michael Smith, Professor of Biochemistry at the University of British Columbia and 1993 Nobel Laureate. In 1988, Novo Nordisk acquired the company and for the next twelve years ZymoGenetics operated as the U.S. research arm of Novo Nordisk. In November 2000, ZymoGenetics became an independent company, and in February 2002, ZymoGenetics completed its initial public offering, raising $120M.
  • 1981 Company founded
  • 1988 ZymoGenetics acquired by Novo Nordisk
  • 2000 Novo Nordisk spins off ZymoGenetics
  • 2002 ZymoGenetics completes IPO
  • 2007 Enters into partnership with Bayer HealthCare to co-commercialize RECOTHROM® Thrombin, topical (Recombinant)
  • 2008 FDA approves RECOTHROM for sale
  • 2009 Enters into global collaboration with Bristol-Myers Squibb for PEG-Interferon lambda

Chief Executive Officer: Douglas E. Williams, Ph.D. (as of January 2, 2009)

Number of Employees: 300 (as of December 17, 2009)

Corporate Headquarters
1201 Eastlake Ave. E, Seattle WA 98102
p: 206.442.6600
www.zymogenetics.com

Incorporated in the state of: Washington

Corporate Counsel: Fenwick & West LLP, Seattle, WA

Independent Auditor: PricewaterhouseCoopers LLP

Annual Report: Available by web or request a copy be mailed

Stock Info

Stock Symbol: ZGEN

Exchange: NASDAQ

CUSIP #: 98985T109

Number of Shares Outstanding: Approx. 85.7 million (as of April 29, 2010)

Stock Split History: No stock splits to date

Transfer Agent:
BNY Mellon Shareowner Services
480 Washington Blvd
Jersey City, NJ 07310
877-261-9288
www.bnymellon.com/shareowner

Mellon Investor Services can answer questions from registered holders of ZymoGenetics stock about lost stock certificates, change of address, number of shares owned, and transfer of certificates to another individual or to/from a broker.

Marketed Products & Product Candidates

Marketed Product: RECOTHROM® Thrombin, topical (Recombinant) approved by U.S. FDA for use as a topical hemostat

Clinical Product Candidates

  • IL-21 as a potential treatment for patients with metastatic melanoma cancer
  • PEG-Interferon lambda (IL-29) for patients with hepatitis C